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บทคดัยอ่ 
การเพิ่มสัดส่วนการมีชีวิตรอดของประชากรในวัยกลางคนมีแนวโน้มท าให้
ประชากรวยัผูสู้งอายุมจี านวนมากขึ้น อายุที่เพิม่ขึ้นมคีวามสมัพนัธ์กบัการเกิด
ความเสื่อมของระบบต่างๆในร่างกาย ซึ่งระบบต่อมไร้ท่อเป็นระบบหนึ่งที่มี
ผลกระทบต่อความบกพร่องที่เกดิขึ้น โดยระบบนี้มคีวามส าคญัในการสงัเคราะห์
ฮอรโ์มนสง่เขา้สูก่ระแสเลอืดและมผีลในการควบคุมหน้าทีก่ารท างานของร่างกาย 
ภาวะกระดกูบาง เกดิจากการลดลงของปรมิาณมวลและความหนาแน่นของกระดกู 
ซึง่กลไกการเกดิโรคค่อนขา้งซบัซอ้น แต่กลไกหนึ่งทีส่ าคญัท าใหเ้กดิภาวะความ
ผดิปกตนิี้คอื ความไมส่มดุลในการสรา้งฮอรโ์มนในวยัผูส้งูอายุ ซึง่มผีลโดยตรงต่อ
เซลลก์ระดกูทัง้ในกระบวนการสรา้งและกระบวนการสลายกระดูก ดงันัน้บทความ
ปริทศัน์นี้จ ึงอธิบายถึงกลไกทางสรรีวิทยาที่เกี่ยวข้องกบัการเจริญเตบิโตของ
กระดูก กระบวนการท าลายและการสรา้งกระดูกใหม่ขึ้นทดแทน นอกจากนี้  ได้
อธบิายผลของฮอร์โมนทีเ่กี่ยวขอ้งกบักระบวนการท างานของกระดูก และความ
บกพร่องของฮอร์โมนทีส่่งเสรมิใหเ้กดิภาวะกระดูกบางในผูสู้งอายุ ตอนทา้ยของ
บทความไดส้รุปถงึการแนวทางป้องกนัและการรกัษาภาวะกระดูกบาง เพื่อคงไว้
ซึง่ความแขง็แรงของกระดกูไวพ้อสงัเขป 
ค ำส ำคญั: ฮอรโ์มน ภาวะกระดกูบาง เซลลก์ระดกู ผูส้งูอายุ ระบบตอ่มไรท้อ่ 
  
 
Abstract 
 
Due to the increasing survival of middle and old age groups, elderly 
population worldwide is increasing. Increasing age is associated with a 
generalized deterioration of systemic organ functions. The endocrine 
system that releases hormones into the blood circulation for regulation of 
bodily functions is one of the physiological systems highly affected by age-
related degeneration. Osteopenia is a progressive loss of bone matrix 
characterized by reduced bone density. The alteration of hormone levels in 
an aging population has a direct impact on bone cells, and therefore the 
potential to develop osteopenia. The pathophysiology of osteopenia is 
complex, but one of the major causes of bone mass loss associated with 
aging appears to be changed within the levels of endogenous hormone 
networks that regulate bone synthesis and breakdown. This brief review 
describes the physiology of bone growth, bone formation and bone 
remodeling. It then describes the effects of hormone regulation, as 
hormone changes with aging, and therefore the likelihood of the 
development of osteopenia. Lastly, this review provides information relating 
to preventative treatment of osteopenia and the maintenance of bone 
mass.  
Keywords: hormone, osteopenia, bone cells, old age and endocrine 
system 
  
บทน า 
In 2015, it was estimated that 900 million people were 
aged 60 and over. This number is expected to rise to 2 
billion in 2050.1 Aging is a gradual process of physical 
degeneration, resulting in decreased physical functions and 
activities in daily living which include slow movement, an 
increased risk of falling and fractures, potentially poor 
quality of life and hospitalization.2,3 With aging, physical 
function impairments are associated with bone weakness 
caused by decreased bone mineral density (BMD). BMD 
and microarchitecture are widely used in medical 
assessments for determining bone strength and quality.4 
Osteopenia is characterized by a progressive decrease in 
BMD and bone function. The prevalence of low BMD levels 
is increasing in elderly people, especially in woman.5 
Pathophysiology of osteopenia is complex. One major 
cause of bone weakness and fracture with aging might be 
from the alteration of hormone networks, particularly those 
involved with bone synthesis and breakdown.6 Hormone 
levels mostly decrease with aging due to impaired function 
of endocrine glands and reduced sensitivity of hormone 
receptors.7 It is important to clarify these hormones that 
affect bone strength. Thus, this review aims to describe the 
physiology of bone growth, bone formation and bone 
remodeling, and effects of hormones on the regulation of 
bone matrix in elderly people. The last part of the review 
article summarizes the present accepted therapeutic 
treatments for prevention of bone loss in osteopenia 
patients.  
 
Physiology of bone growth, bone 
formation and bone remodeling 
 
Bone is a tissue characterized by its hardness and its 
ability to repair and regeneration. It is a specialized tissue 
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that supports the framework of the body, protects vital 
organs, controls calcium-phosphate and acid-base 
homeostasis, and provides mineral, fat and growth factor 
storages.8 During fetal development, most bones are 
modeled in cartilage and then transformed into normal 
healthy bone by ossification, namely, enchondral and 
intramembranous bone formations.9 During growth, the 
ends of long bones (epiphyses) are separated from the 
shaft of the bone by an epiphyseal plate. The bone 
increases in length due to the influence of hormone 
networks.9 The growth stops after these epiphyseal plates 
unite with the shaft. Bone cells consist of osteocytes, 
osteoblasts and osteoclasts. These cells regulate 
ossification or osteogenesis. Osteoblasts, arising from 
mesenchymal stem cells, are modified fibroblasts. They are 
responsible for the synthesis of extracellular organic matrix 
and mineralization during bone formation.10 The 
differentiation and proliferation of osteoblasts are regulated 
by the Wnt/beta-catenin pathway.11 Osteoblasts also play a 
role in bone resorption via receptor activation of nuclear 
factor-kappa beta ligands (RANKL) that interacts with 
receptors (RANK) on the surface of preosteoblasts.11 In 
contrast, osteoblasts secrete osteoclast inhibiting factor 
namely osteoprotegerin (OPG) that inhibits the binding of 
RANKL to RANK and prevents osteoclasts proliferation and 
differentiation.11 Osteoclasts are part of the monocyte 
family, and arise from hematopoietic stem cells. They are 
responsible for bone resorption by secretion of massive acid 
and proteinases for organic matrix degradation.12 
Osteocytes act in mature bone tissue and differentiate into 
active osteoblasts. Osteocytes also control the function of 
osteoclasts to resorb bone and osteoblasts to form 
bone.13,14 
The basic mechanism of osteogenesis and bone 
remodeling (Figure 1) occurs via the differentiation of 
osteoprogenitor cells to become osteoblasts. The osteoblast 
creates osteoid (organic component) and inorganic 
phosphate component, made from crystal salt. Both 
components are needed for bone matrix synthesis and 
mineralization. Some osteoblasts become osteocytes when 
they are contained within the bone matrix and stop osteoid 
secretion. The production of osteocytes is guided by the 
need for bone remodeling. Osteocyte is responsible for 
mechanical loading by undergoing apoptosis releasing pro-
inflammatory cytokines that cause osteoclast to the site of 
injury. Remodeling requires mineralization of bone by 
osteoclast activity, followed by the production of bone matrix 
through the activities of osteoblasts. Subsequently, 
osteoblasts secrete, synthesize and mineralize osteoid to 
lay down on new bone which results in a repair of defective 
bone. Bone remodeling is therefore composed of three 
processes as follows. First, in resorption process, 
osteoclasts break down the old bone. Second, in reversal 
process, mononuclear cells appear on resorbed bone 
surface. Last, in bone formation process, osteoblasts form 
new bone cells replacing the old bone cells.15 Bone 
remodeling helps adjust the skeleton to form appropriate 
surface modification when exposed to physiological and 
mechanical forces. Therefore, the balancing between bone 
formation and bone resorption is necessary to maintain 
architecture, mineralization and bone strength. The 
regulation of bone remodeling also involves insulin-like 
growth factor I (IGF-I), vitamin D and numerous hormones 
including parathyroid hormone, calcitonin, estrogen, 
testosterone, thyroid hormone, cortisol and growth hormone. 
 
 
 
 Figure 1  The basic mechanism of osteogenesis and 
bone remodeling.  
Abbreviations: RANKL, receptor activator for nuclear factor kappa beta ligand; RANK, 
receptor activator for nuclear factor kappa beta; OPG, osteoprotegerin; IL-1, interleukin 
1; IL-6, interleukin 6; TNF-α, tumor necrosis factor α. 
 
 
Hormones regulating bone matrix and 
their potential to develop osteopenia 
     
Parathyroid hormone, calcitonin and vitamin D 
Parathyroid hormone (PTH) is secreted by the 
parathyroid gland while calcitonin (CT) is secreted by the 
parafollicle cells of the thyroid gland. Both hormones are 
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key hormones to regulate blood calcium and phosphate 
homeostasis.9 PTH stimulated calcium resorption from bone 
by coupling with its receptors on the bone cells. Calcium 
ions from the bone are released into extracellular fluid, 
which results in an increasing blood calcium.9 Conversely, 
CT reduces blood calcium by inhibiting calcium resorption 
from the bone.9 Hence, PTH and CT are the main 
hormones for regulation of bone turnover and maintaining 
blood calcium. In bone resorption phase, PTH mainly acts 
on osteoblasts and pre-osteoblastic cells through 
expression of RANKL on the surface of hematopoietic 
precursors of osteoclasts for increasing number of 
osteoclasts which enhances bone resorption and blood 
calcium.16,17 In bone formation phase, PTH directly 
regulates bone morphologic protein (BMP) signaling to 
induce bone marrow stroma differentiation into 
osteoblasts.18 PTH also enhances osteoblastogenesis and 
decreases osteoblast apoptosis.19,20 PTH, however, 
stimulates IGF-I to synthesize bone matrix.21 Conversely, 
CT inhibits osteoclast activity and causes reduction of bone 
resorption, mediated by interruption of cytoskeletal 
organization and the regulation of cAMP/PKA signal 
pathway leading to decreased blood calcium.22 Furthermore, 
Vitamin D is essential for mineralization of bone and 
stimulation of bone turnover. Vitamin D is metabolized into 
active vitamin D, namely 1,25-dihydroxycholecalciferol 
(1,25-(OH)2D3), for regulation of calcium metabolism. 
Vitamin D increases number of osteoclast through 
enhancing RANKL expression. The primary action of 1,25-
(OH)2D3 is to increase blood calcium and phosphate 
absorption from gut.23 It also works together with PTH to 
mobilize calcium from bone and to conserve calcium from 
urine.24 Moreover, 1,25-(OH)2D3 is important for 
chondroblasts differentiation resulting in the production of 
collagen to form endochondral bone.25 Thus, the bone 
remodeling process requires PTH, vitamin D and CT to 
regulate bone metabolism.  
Aging is associated with increasing serum parathyroid 
hormone levels responsible for changes of bone metabolism 
and bone density.26 Deficiencies of calcium deposit in bone 
and vitamin D are present in hyperparathyroidism because 
of lack of vitamin D and calcium reabsorption which then 
stimulates PTH secretion.27 Therefore, the increasing serum 
PTH level in patients is due to the increased number of 
osteoclasts, mediated by stimulation of the expression of 
RANKL/osteoprotegerin (OPG) ratio.16 The increase in the 
amount of RANKL leads to increased numbers of 
osteoclasts. For this reason, bone resorption is greater than 
bone formation, resulting in the development of osteopenia. 
With increasing age, many factors also cause an increase 
in PTH levels. Common factors include impaired renal 
function, the use of loop diuretic drugs, decreasing renal 
calcium reabsorption and decreasing serum 1,25-(OH)2D3.
28 
These factors decrease calcium deposit in bone and result 
in increasing risk of bone fracture,  low bone density and 
strength.  
Hormone replacement therapy (HRT) is a common 
method employing drug use for mitigation of bone loss. PTH 
is accepted as an effective treatment for osteopenia 
patients. The low dose injection of PTH promotes cortical 
and trabecular bone growth.29,30 Calcium and vitamin D 
supplement are also used for osteopenia patients with low 
calcium intake and vitamin D deficiency.31 However, 
prolonged use of high dose PTH causes increasing bone 
resorption. Hence, suitable doses of supplement are 
necessary for given patients. Depending on the diagnosis 
and severity of diseases, patients should consult with their 
physician about the use of HRT.  
 
Estrogen  
Estrogen is the major female sex hormone for regulating 
female reproductive system. Estrogen synthesis is 
controlled by the hypothalamic-pituitary-ovarian axis and is 
secreted by the ovaries to regulate female secondary sex 
characteristics.9  Moreover, estrogen has a pivotal role in 
bone growth and development of the skeletal system.32 It is 
needed for epiphyseal plate closure during bone growth, 
both in men and women.32 Estrogen has a direct action on 
bone cells including osteocytes, osteoblasts and 
osteoclasts.32 Estrogen regulates bone density and strength 
by balancing both osteoblast and osteoclast activities.33 The 
role of estrogen on bone metabolism is regulated by pro-
inflammatory cytokines including interleukin 1 (IL-1), 
interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) and 
prostaglandin E2 (PGE2). These factors increase the 
number of osteoclasts and cause an enhanced bone 
resorption.34 Studies have shown that estrogen acts on the 
estrogen receptor α and prevents bone loss by inducing up-
regulation of the Fas ligand (FasL), leading to osteoclast 
apoptosis.35 Estrogen has a potential to regulate bone 
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remodeling by increasing osteoblast and osteoclast 
proliferations through the regulation of TNF-β.36 In female 
adults, if plasma estrogen is lower than the optimal level,  
low bone mineral density usually occurs.37 The imbalance of 
estrogen production can occur during reproductive age in 
women due to poor nutrition, stress and heavy exercise. 
Estrogen supplement from foods including soil milk, bean, 
and sesame seeds are essential to mitigate bone loss. 
These products are safe and do not interrupt the 
reproductive cycle.  
Estrogen deficiency is commonly found in aging women 
who go through the menopause, usually between 45 - 55 
years old.37 Menopause appears when menstruation ceases 
permanently. It is the most common cause of osteopenia 
and increased bone fracture risk.37 Estrogen deficiency 
activates TNF which further produces T cells by directly 
stimulating interleukin 7 (IL-7) and receptor activator of 
RANKL aggregation. This results in osteoclast proliferation 
and impaired bone density.38 Additionally, estrogen 
deficiency also inhibits bone formation by increasing 
osteoblast apoptosis, oxidative stress and nuclear factor 
kappa beta (NF-κB) activity in osteoblastic cells.36 
Therefore, estrogen deficiency leads to increasing bone loss 
and risk of bone fractures.  
Estrogen replacement therapy is necessary to enhance 
bone mass and strength in elderly women. In the past, 
estrogen and progestin administration was widely accepted 
in women with menopause. However, nowadays, the 
administrations of both hormones are not recommended 
because of their potential to develop breast cancer, bone 
fracture and stroke.39 Hence, prolonged use of either 
estrogen or progestin should be concerned with the 
mentioned risks and side effects.  
 
Androgen hormone (mainly testosterone)  
Testosterone is a main androgen hormone and plays 
significant roles in the growth and development of 
secondary male sex characteristics.9 Testosterone synthesis 
is controlled by the hypothalamic-pituitary-testicular axis. 
Testosterone is the major circulating androgen hormone in 
men, secreted by the Leydig cells of the testes. Androgen 
regulates sperm production and masculinization.9 It also 
affects bone growth and development activity, particularly in 
men. Androgen acts on bone tissues directly via androgen 
receptors (ARs) and indirectly by aromatization of estrogen 
receptors.40 Androgen increases the number of ARs in 
osteoblasts,41 suppresses osteoblast apoptosis,42 enhances 
IL-1β production43 and stimulates mitogenesis and 
differentiation in bone cells.44 Androgen, interacting with 
ARs, directly inhibits osteoclast formation and bone 
resorption associated with the RANKL pathway.45 Hence, 
androgen has a strong anabolic effect on bone formation by 
stimulating osteoblast proliferation and inhibiting osteoclast 
differentiation.  
Andropause is characterized by age-related changes in 
male sex hormones, particularly testosterone, found in men 
between the ages of 30-69.46 Reducing bone mineral 
density in older men is caused by testosterone deficiency. 
The mechanism of bone mineral density loss occurs 
through increasing numbers of hematopoietic precursors 
forming osteoclasts45 and osteoclast proliferation via 
expressing RANKL activity.47 Clinically, sex hormone 
binding globulin (SHBG) is gradually increased with aging. 
SHBG has a high affinity to bind to testosterone. Hence, 
testosterone usually is found to bind to SHBG, leading to 
decreasing testosterone availability for interacting with its 
receptors on bone cells.48 A low level of testosterone with a 
high level of SHBG is associated with decreasing bone 
mineral density and increasing risk of bone fracture.48,49 
Therefore, such levels of SHBG and testosterone in men 
cause an increased risk of osteopenia.  
Testosterone replacement therapy is usually used to 
maintain optimal plasma testosterone level, particularly in 
hypogonadal state for the improvement of bone mineral 
density.50 However, testosterone administration has many 
side effects including acne, prostate abnormality, sleep 
apnea and cardiovascular effect.50 Nevertheless, 
testosterone intake is sometimes used in some cases 
based on recommendation of physicians. 
 
Thyroid hormones  
Thyroid hormones (T3, T4) are essential for linear bone 
development and accomplishment of peak bone mass.51 
Thyroid hormones are synthesized from iodide and the 
amino acid tyrosine in the follicular cells of the thyroid 
gland. Thyroid hormone secretion is controlled by the 
hypothalamic-pituitary-thyroid axis.9 Thyroid releasing 
hormone (TRH) and thyroid stimulating hormone (TSH) are 
released by the hypothalamus and pituitary gland, 
respectively. Both hormones regulate the synthesis of T3 
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and T4.9 TSH is classified as a negative regulator of bone 
remodeling activity.52 The TSH receptors are present in 
thyroid follicular cells and also found in osteoblasts and 
osteoclasts.53 T3 directly stimulates osteoblast activity by 
the synthesis of bone matrix protein, namely osteopontin 
and osteocalcin, and then regulates osteoblast proliferation 
and differentiation through IGF-I transcription.54 
Furthermore, it acts indirectly on osteoblasts and stimulates 
osteoclast proliferation through the regulation of OPG and 
RANKL.55 However, T3  stimulates IL-6 and IL-8 production, 
extends the synthesis of type I collagen and osteocalcin, 
which in turn enhance proliferation and apoptosis of 
osteoblasts.56 Additionally, the interaction between T3 and 
T4 and 1,25-(OH)2D3 is required for osteoclasts formation.
57 
Therefore, T3 and T4 play a crucial role in bone turnover by 
enhancing osteoblast to form bone via synthesis of bone 
matrix protein. They also stimulate cytokines production, 
expression of OPG and RANKL and the interaction with 
1,25-(OH)2D3 for regulation of bone resorption.  
As people age, the production of thyroid hormones and 
the regulation of metabolism change. These lead to thyroid 
disease in elderly people.58 Thyroid disease is characterized 
by abnormalities of thyroid functions, commonly either 
hyperthyroidism or hypothyroidism in both elderly men and 
women. Thyrotoxicosis is a condition caused by low levels 
of serum TSH, but overproduction of serum T3 and T4. In 
adults with thyrotoxicosis, there is an increasing of bone 
turnover due to shortening of bone remodeling cycle which 
leads to a decreased bone density and an increased risk of 
bone fractures.59 Hyperthyroidism patients often show an 
increased serum IL-6, which stimulates the recruitment of 
osteoclasts leading to an increasing bone loss.60 In elderly 
men with subclinical hyperthyroidism, increasing risk of hip 
fracture is observed.61 In addition, both pre-menopause and 
post-menopause with subclinical hyperthyroidism show a 
decreased femoral bone mass density (BMD) and a high 
risk of bone fracture.62 However, in hypothyroidism, there is 
a decrease in bone turnover with impaired bone formation 
and resorption phases, resulting in a prolonged duration in 
bone remodeling cycle. Patients older than 50 years of age 
and 2 years following the diagnosis of primary iodopathic 
hypothyroidism were found to increase risk of bone 
fracture.63 Older men aged above 65 years old with 
subclinical hypothyroidism are also noted to have an 
increased risk of hip fracture.63 The reason for an increasing 
risk of bone fracture in hypothyroidism is because of a 
reduced amount of T3 and T4 leading to a decrease in 
bone turnover with poor bone quality. Therefore, the 
imbalances of thyroid hormones impact both bone density 
and bone strength. Either hyperthyroidism or hypothyroidism 
increases a risk of bone fractures. In hyperthyroidism 
patients, the bone mineral densities are decreased. 
Hypothyroidism patients, however, have an increase in 
bone densities with poor bone quality.  
Thyroid hormone replacement therapy is essential for 
patient with hypothyroidism, a condition caused by a low 
level of plasma thyroid hormone. Prolonged administration 
of exogenous thyroxin in subclinical hypothyroidism results 
in a high risk of low bone mineral density.64 Therefore, 
thyroid hormone treatment is not recommended for the 
improvement of bone strength in patients with osteopenia. 
Thyroid hormone treatment is quite specific for each patient 
based on pathophysiology of disease to avoid adverse 
effects.  
 
Growth hormone and insulin-like growth factor I 
system 
Growth hormone (GH) has effects on skeletal growth 
during childhood and puberty. Bone mass is gradually 
increased until peak bone mass is reached at 20 - 30 years 
of age.9 The synthesis of GH is controlled by growth 
hormone releasing hormone (GHRH) in the hypothalamus. 
GH also regulates longitudinal bone growth by the 
production of hepatic insulin-like growth factor I (IGF-I).9 
IGF-I and IGF-II are peptide hormones with similar 
structures to insulin. IGF-II is required for embryonic 
development but IGF-I has a crucial role in human growth 
throughout the development.65 GH is mediated through IGF-
I production and is important for bone growth and 
metabolism.66 It has a direct effect on pre-chondrocyte 
proliferation without the action of IGF, resulting in an 
increase in longitudinal epiphyseal plate growth.67 Moreover, 
GH directly increases the number of osteoblasts and 
stimulates differentiated function of osteoblasts.68 It is 
mediated via the up-regulation of IGF-I to induce osteoblast 
proliferation.69 GH regulates bone resorption by producing 
osteoclast proliferation and differentiation through enhanced 
1,25-(OH)2D3 and IL-6 activities.
70,71 Therefore, GH/IGF-I 
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system is a direct action on bone growth, bone formation 
and bone remodeling cycle. 
The regulation of the GH/IGF-I system contributes to 
bone mass loss in aged groups. This is because the 
secretion of GH is gradually decreased as an individual 
ages,  by decreasing the activity of GHRH, reducing sex 
hormones, enhancing somatostatin secretion, poor sleeping 
pattern, malnutrition, and increasing negative feedback from 
GH and IGF-I.72-74 Furthermore, the serum IGF-I 
concentration also decreases with age and is related to the 
decrease in BMD both in post-menopausal and andropausal 
states.75,76 Hence, the decrease in GH/IGF-I system may 
have impacts on age-related bone weakness, due to the 
reduction of osteoblast proliferation and the increase in 
osteoblast apoptosis and osteoclast proliferation.  
Biosynthesized growth hormone treatment is used for 
hypopituitarism in adults on aspects of bone mineral 
density, calcium balance and bone metabolism. GH 
treatment for six months was found to increase bone 
turnover but did not affect bone mass.77 A recent report 
showed that ten years of growth hormone treatment 
enhance bone mineral density and further decrease the risk 
of bone fracture. However, this treatment does not affect 
quality of life in postmenopausal woman with 
osteoporosis.78  
 
Glucocorticoids   
Glucocorticoids, mainly cortisol, maintain bone 
maturation and have a potential to affect the development 
and growth of the skeleton.9 Glucocorticoids are produced 
by the adrenal glands (part of adrenal cortex) via the 
regulation of the hypothalamic-pituitary-adrenal axis.9 The 
regulation of glucocorticoid secretion depends on the 
release of corticotropin releasing hormone (CRH) and 
corticotropin hormone (ACTH).9 Glucocorticoids exert both 
direct and indirect actions on bone cells including 
osteoblasts, osteocytes and osteoclasts.79 Glucocorticoids 
decrease osteoblast proliferation and increase osteoblast 
apoptosis through down-regulation of type I collagen and 
osteocalcin.80 It also enhances osteoclast proliferation 
through stimulation of RANKL expression.81 Thus, bone 
mass loss is observed from decreasing osteoblast 
proliferation and increasing osteoblast apoptosis and 
osteoclast proliferation. The mechanisms of glucocorticoids 
and other hormones mediated through bone cells are 
showed in Figure 2.  
Normally blood cortisol level is highest in the early 
morning.82 The level of cortisol gradually increases with 
age. As people age, increasing evening cortisol levels are 
found in serum and saliva.83,84 The increase in cortisol 
levels in urine is related to a high risk of bone fractures 
both in men and womn.85 Additionally, increased saliva 
cortisol was related to a decrease in lumbar spine BMD in 
elderly men and women.86 The correlation between saliva 
levels and bone density is observed in both human and 
rodents. The increasing of corticosterone is found in aged 
mice and associated with decreased strength of bone.87 
Therefore, as people age, serum cortisol levels gradually 
increase which can be linked to the loss of bone mass and 
the increased risk of bone fracture. Prolonged use of 
glucocorticoids drugs, for treatment of allergy, inflammatory 
and arthritis, impacts BMD. Appropriate doses of drug 
treatment should be recommended by clinician to avoid 
adverse effects. 
 
 
 
 Figure 2  The mechanism of glucocorticoids and other 
hormones mediated through bone cells.  
Abbreviations: RANKL, receptor activator for nuclear factor kappa beta ligand; RANK, 
receptor activator for nuclear factor kappa beta; OPG, osteoprotegerin; GH, growth 
hormone; IGF-I, insulin-like growth factor I; CT, calcitonin; T3 and T4, thyroid hormone; 
PTH, parathyroid hormone; IL-1, interleukin 1; IL-6, interleukin 6; TNF-α, tumor 
necrosis factor α. 
 
Therapeutic treatment for 
preventing bone loss in osteopenia 
condition 
Osteopenia is a common problem of thin, weakened 
bone with a high risk of fracture. Elderly people, both men 
and women, are at a high risk of osteopenia due to the 
imbalance of hormone production that helps maintain bone 
density. Preventive treatment of osteopenia is important to 
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maintain bone mass including the following.88 These 
individuals need calcium supplement. The recommended 
level for calcium intake in premenopausal women and men 
is about 1,000 milligrams per day including calcium from 
foods and beverages. The recommended calcium intake in 
postmenopausal persons, however, is about 1,200 
milligrams per day. The major sources of calcium are milk, 
yogurt, and green vegetables.88 
In addition to calcium, vitamin D supplement is also 
needed. The recommended dose for people aged between 
55 - 70 years old is 800 international units of vitamin D per 
day. Additionally, they should consume enough protein 
supplements and should limit alcohol, caffeine and salt 
intake.88 It is also recommended that these individuals take 
an adequate level of exercise which is about 30 minutes, 
three times per week. Regular exercise improves bone 
mass and muscle strength in elderly people.88 Exercise 
training programs in elderly people could promote strength, 
endurance, balance and flexibility.89 It is recommended to 
stop smoking since it is a factor that increases bone loss. 
Smoking cessation can reduce the risk of bone weakness.88 
Prolonged high doses of some medications can increase 
the risk of bone loss. Therefore, doctors should check the 
appropriate dose for patients and also decrease or 
discontinue when it is possible. Examples of such 
medications are drugs in the glucocorticoids, heparin and 
antiepileptic groups.88 Hormone replacement therapy is 
used for osteopenic patients based on individual 
assessment. For example, PTH is recommended for 
postmenopausal women with severe spine and hip 
osteoporosis. Estrogen and progesterone are recommended 
for young women following bilateral ovary removal but the 
use of the two hormones for postmenopausal women is not 
recommended.88  
 
Conclusions 
Hormones are necessary to regulate bone growth and 
metabolism by acting mainly on bone cells for regulating 
bone turnover. Hormones gradually change with age both in 
men and women and this change could be the cause of 
osteopenia. Osteopenia is caused by low bone mineral 
density and increases the risk of bone fracture in elderly 
people. Hence, preventive treatments to mitigate the effects 
of osteopenia should be considered by clinicians. The 
treatments include taking dietary supplements, doing 
exercise, taking medications and doing hormone 
replacement therapy.  
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